Cargando…

Comparison of (68)Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer

PURPOSE: To assess (68)Ga-PSMA PET/CT for detection of low- and intermediate-risk prostate cancer (PCa), high-risk PCa in comparison with mpMRI, respectively, and to determine which of low- and intermediate-risk PCa are more likely to be detected by (68)Ga-PSMA PET/CT. METHODS: We conducted a retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Chuanchi, Tang, Yongxiang, Deng, Zhihe, Yang, Jinhui, Zhou, Ming, Wang, Long, Hu, Shuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837766/
https://www.ncbi.nlm.nih.gov/pubmed/35147810
http://dx.doi.org/10.1186/s13550-022-00881-3
_version_ 1784649972480737280
author Zhou, Chuanchi
Tang, Yongxiang
Deng, Zhihe
Yang, Jinhui
Zhou, Ming
Wang, Long
Hu, Shuo
author_facet Zhou, Chuanchi
Tang, Yongxiang
Deng, Zhihe
Yang, Jinhui
Zhou, Ming
Wang, Long
Hu, Shuo
author_sort Zhou, Chuanchi
collection PubMed
description PURPOSE: To assess (68)Ga-PSMA PET/CT for detection of low- and intermediate-risk prostate cancer (PCa), high-risk PCa in comparison with mpMRI, respectively, and to determine which of low- and intermediate-risk PCa are more likely to be detected by (68)Ga-PSMA PET/CT. METHODS: We conducted a retrospective analysis of patients who had undergone a prostate biopsy and/or radical prostatectomy and who were scanned with (68)Ga-PSMA PET/CT and mpMRI between June 2019 and March 2021. The mpMRI images were scored with the Prostate Imaging-Reporting and Data System Version 2.1 (PI-RADS) and were classified as either negative (PI-RADS 1–3) or positive (PI-RADS 4–5). Suspicious (68)Ga-PSMA PET/CT lesions were reviewed for each relevant patient and classified by double-trained board-certified nuclear medicine physicians. The results were evaluated with the histopathological outcome. All patients were classified according to the D’Amico classification, and the clinical data were combined for stratified analysis. RESULT: A total of 101 patients who were pathologically diagnosed with PCa were analyzed. Of the 101 patients, 88 (80.6%) patients presented with a pathologic mpMRI, and 85 (79.1%) with a pathologic (68)Ga-PSMA PET/CT. In the high-risk PCa cohort, (68)Ga-PSMA PET/CT was positive in 64/66 (97.0%) patients and yielded a higher detection rate than that for the mpMRI patients (58/66, 87.9%; p < 0.05). However, mpMRI provided superior diagnostic confidence in identifying low- and intermediate-risk PCa (30/35, 85.7% vs. 21/35, 60.0%; p < 0.05). When the age threshold exceeded 62.5 years and the serum prostate specific antigen (PSA) threshold exceeded 9.4 ng/ml, a higher uptake of PSMA was more likely to occur in the lesions of low- and intermediate-risk PCa. CONCLUSION: The diagnostic performance of (68)Ga-PSMA PET/CT was superior to that of mpMRI in the high-risk PCa cohort, which was consistent with prior studies. Furthermore, in the initial diagnosis of low- and intermediate-risk PCa, we found that mpMRI showed a higher diagnostic accuracy than (68)Ga-PSMA PET/CT did. Low- and intermediate-risk PCa patients with a PSA ≥ 9.4 ng/ml and age ≥ 62.5 years were more likely to have a positive (68)Ga-PSMA PET/CT result. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-022-00881-3.
format Online
Article
Text
id pubmed-8837766
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-88377662022-02-23 Comparison of (68)Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer Zhou, Chuanchi Tang, Yongxiang Deng, Zhihe Yang, Jinhui Zhou, Ming Wang, Long Hu, Shuo EJNMMI Res Original Research PURPOSE: To assess (68)Ga-PSMA PET/CT for detection of low- and intermediate-risk prostate cancer (PCa), high-risk PCa in comparison with mpMRI, respectively, and to determine which of low- and intermediate-risk PCa are more likely to be detected by (68)Ga-PSMA PET/CT. METHODS: We conducted a retrospective analysis of patients who had undergone a prostate biopsy and/or radical prostatectomy and who were scanned with (68)Ga-PSMA PET/CT and mpMRI between June 2019 and March 2021. The mpMRI images were scored with the Prostate Imaging-Reporting and Data System Version 2.1 (PI-RADS) and were classified as either negative (PI-RADS 1–3) or positive (PI-RADS 4–5). Suspicious (68)Ga-PSMA PET/CT lesions were reviewed for each relevant patient and classified by double-trained board-certified nuclear medicine physicians. The results were evaluated with the histopathological outcome. All patients were classified according to the D’Amico classification, and the clinical data were combined for stratified analysis. RESULT: A total of 101 patients who were pathologically diagnosed with PCa were analyzed. Of the 101 patients, 88 (80.6%) patients presented with a pathologic mpMRI, and 85 (79.1%) with a pathologic (68)Ga-PSMA PET/CT. In the high-risk PCa cohort, (68)Ga-PSMA PET/CT was positive in 64/66 (97.0%) patients and yielded a higher detection rate than that for the mpMRI patients (58/66, 87.9%; p < 0.05). However, mpMRI provided superior diagnostic confidence in identifying low- and intermediate-risk PCa (30/35, 85.7% vs. 21/35, 60.0%; p < 0.05). When the age threshold exceeded 62.5 years and the serum prostate specific antigen (PSA) threshold exceeded 9.4 ng/ml, a higher uptake of PSMA was more likely to occur in the lesions of low- and intermediate-risk PCa. CONCLUSION: The diagnostic performance of (68)Ga-PSMA PET/CT was superior to that of mpMRI in the high-risk PCa cohort, which was consistent with prior studies. Furthermore, in the initial diagnosis of low- and intermediate-risk PCa, we found that mpMRI showed a higher diagnostic accuracy than (68)Ga-PSMA PET/CT did. Low- and intermediate-risk PCa patients with a PSA ≥ 9.4 ng/ml and age ≥ 62.5 years were more likely to have a positive (68)Ga-PSMA PET/CT result. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-022-00881-3. Springer Berlin Heidelberg 2022-02-11 /pmc/articles/PMC8837766/ /pubmed/35147810 http://dx.doi.org/10.1186/s13550-022-00881-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Zhou, Chuanchi
Tang, Yongxiang
Deng, Zhihe
Yang, Jinhui
Zhou, Ming
Wang, Long
Hu, Shuo
Comparison of (68)Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer
title Comparison of (68)Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer
title_full Comparison of (68)Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer
title_fullStr Comparison of (68)Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer
title_full_unstemmed Comparison of (68)Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer
title_short Comparison of (68)Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer
title_sort comparison of (68)ga-psma pet/ct and multiparametric mri for the detection of low- and intermediate-risk prostate cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837766/
https://www.ncbi.nlm.nih.gov/pubmed/35147810
http://dx.doi.org/10.1186/s13550-022-00881-3
work_keys_str_mv AT zhouchuanchi comparisonof68gapsmapetctandmultiparametricmriforthedetectionoflowandintermediateriskprostatecancer
AT tangyongxiang comparisonof68gapsmapetctandmultiparametricmriforthedetectionoflowandintermediateriskprostatecancer
AT dengzhihe comparisonof68gapsmapetctandmultiparametricmriforthedetectionoflowandintermediateriskprostatecancer
AT yangjinhui comparisonof68gapsmapetctandmultiparametricmriforthedetectionoflowandintermediateriskprostatecancer
AT zhouming comparisonof68gapsmapetctandmultiparametricmriforthedetectionoflowandintermediateriskprostatecancer
AT wanglong comparisonof68gapsmapetctandmultiparametricmriforthedetectionoflowandintermediateriskprostatecancer
AT hushuo comparisonof68gapsmapetctandmultiparametricmriforthedetectionoflowandintermediateriskprostatecancer